For those living with progressive multiple sclerosis, time is not a neutral force — it is the disease itself, advancing without pause. The Octopus trial, a UK-based adaptive study now extending into Australia through the PLATYPUS program, is attempting to meet that urgency with a new kind of scientific architecture: testing multiple treatments simultaneously, cutting what fails, and pursuing what shows promise. Its first results have done exactly that — discontinuing metformin and advancing alpha lipoic acid — offering a signal, if not yet proof, that the model and perhaps the molecule are wor
World-first adaptive MS trial shows alpha lipoic acid promise, expands to Australia
People with progressive MS face inevitable disease progression; effective treatments could slow disability and provide hope for this population with significant unmet medical needs.
Time is not our friend at all with progressive MS
Mark
So the trial stopped testing metformin but kept alpha lipoic acid. What exactly did the early results show that made the difference?
Mimi
Stage 1 measured clinical outcomes and brain atrophy over time. Alpha lipoic acid showed enough of a signal—enough promise—to justify moving forward. Metformin didn't meet that threshold.
Luke
But we should be clear: Stage 1 results are not proof the drug works. They're an early indicator. That's why Stage 2 exists—to test whether it actually slows disability progression.
Mark
Right. So why is the adaptive trial model such a big deal compared to how trials usually work?
Mimi
Normally you test one drug, wait years for results, and if it fails, you start over with the next one. Octopus tests multiple treatments simultaneously and makes decisions as evidence comes in. You can kill a failing treatment quickly and add new ones.
Luke
Which sounds efficient, but it also means the trial design itself is more complex. You're managing multiple arms, different endpoints, real-time decision-making. The logistics are harder.
Mark
And Australia is joining at Stage 2. Why does that matter?
Mimi
Australia gets to participate in a world-first trial and contribute to the international search for progressive MS treatments. But also, it accelerates recruitment. More sites, more participants, faster answers.
Luke
Though we should note that Stage 2 results won't come for three years. The adaptive model speeds things up, but it's not instant.
Mark
What's the human reality here? Why does speed matter so much for progressive MS?
Mimi
Because the disease is relentless. It doesn't stop. A treatment that slows progression, even a little, can change someone's life trajectory. And people with progressive MS have very few options right now.
Luke
That's the unmet need—there aren't many effective treatments available. So hope is real, but it's also conditional on whether alpha lipoic acid actually works in Stage 2.
Mark
Fair. What happens next?
Mimi
Recruitment expands to Perth and Hobart. Participants in Stage 2 either get alpha lipoic acid or usual care, and researchers measure whether the drug slows disability over three years. New treatment arms may be added if other promising therapies emerge.
Luke
And if alpha lipoic acid doesn't show benefit in Stage 2, it gets discontinued too. The adaptive model works both ways.
Le Pouls
- Progressive MS has no effective treatments to slow its course, leaving patients facing inevitable functional decline with little recourse — the unmet need is vast and the human cost is measured in lost years and lost capacity.
- The Octopus trial's adaptive design breaks from the slow, sequential logic of traditional clinical research, running multiple treatment arms at once and making real-time decisions as evidence accumulates.
- Metformin has already been cut from the trial for failing to meet advancement thresholds — a sign the model works — while alpha lipoic acid has cleared Stage 1 and will now be tested for its ability to slow disability progression.
- Australia's PLATYPUS extension, led by Griffith University's Professor Simon Broadley, has opened recruitment at Gold Coast University Hospital and is expanding to Perth and Hobart to broaden participation and accelerate enrollment.
- For participants like Paralympian Janine Watson, the stakes are intimate and immediate — an effective therapy would not just slow disease, it would return something the illness steadily takes: time.
For those living with progressive multiple sclerosis, time is not a neutral force — it is the disease itself, advancing without pause. The Octopus trial, a UK-based adaptive study now extending into Australia through the PLATYPUS program, is attempting to meet that urgency with a new kind of scientific architecture: testing multiple treatments simultaneously, cutting what fails, and pursuing what shows promise. Its first results have done exactly that — discontinuing metformin and advancing alpha lipoic acid — offering a signal, if not yet proof, that the model and perhaps the molecule are worth believing in.
A clinical trial testing multiple treatments for progressive MS simultaneously has delivered its first results, and the model is working as designed. The UK-based Octopus trial, funded by the MS Society, has discontinued metformin after it failed to meet the threshold for advancement, while alpha lipoic acid showed sufficient early promise to continue into the next stage. The ability to cut an ineffective treatment quickly — freeing resources and participant time — is precisely what the adaptive design was built to do.
Unlike traditional trials that test one treatment at a time and wait years before moving to the next, Octopus runs multiple arms in parallel, allowing researchers to respond to evidence in real time. Stage 1 findings for alpha lipoic acid measured clinical outcomes and brain atrophy, and while they are not proof of efficacy, they are a signal worth pursuing. Stage 2 will determine whether the compound can genuinely slow disability progression over the next three years.
Australia has joined the effort through PLATYPUS, the national extension of Octopus, led by Griffith University neurologist Professor Simon Broadley. Recruitment is underway at Gold Coast University Hospital, with new sites planned for Perth and Hobart. MS Australia CEO Rohan Greenland describes the expansion as both a scientific and moral opportunity — progressive MS represents one of neurology's largest unmet needs, and Australian participants gain access to a potential new therapy while contributing to a world-first research effort.
The urgency is personal for those living with the disease. Paralympian Janine Watson, a member of MS Australia's Lived Experience Expert Panel, puts it plainly: with progressive MS, delay is itself a cost. The adaptive trial model exists, in part, as an answer to that reality — a way to move faster, waste less, and focus on what might actually help.
A clinical trial designed to test multiple treatments for progressive multiple sclerosis at the same time has produced its first results, and they are moving the research forward. The Octopus trial, based in the UK and funded by the MS Society, found that alpha lipoic acid showed enough early promise in its initial stage to warrant continued testing. A second treatment, metformin, did not meet the threshold for advancement and has been discontinued from the study.
What makes Octopus distinctive is its structure. Rather than the traditional approach of testing one treatment, waiting years for results, and only then moving to the next candidate, this trial runs multiple treatment arms in parallel. As evidence accumulates, researchers can make real-time decisions: keep testing what works, stop what doesn't, and introduce new candidates as they emerge. This adaptive design compresses the timeline for discovery. The first interim results from Octopus demonstrate the model working as intended—metformin's discontinuation shows that the trial can eliminate ineffective treatments quickly, freeing resources and participant time for more promising avenues.
Australia is now part of this effort through PLATYPUS, the Australian extension of Octopus, which joined the international trial at Stage 2. Griffith University neurologist Professor Simon Broadley leads the Australian arm, while Professor Jeremy Chataway of University College London directs the broader study. Broadley explains the stakes plainly: people with progressive MS face an inevitable decline in function. A treatment that can slow that progression, even modestly, changes the trajectory of someone's life. The Stage 1 findings for alpha lipoic acid—which measured clinical outcomes and brain atrophy over time—are not proof of efficacy, but they are a signal worth pursuing. Stage 2 will test whether the compound can actually slow disability progression over the next three years.
Recruitment in Australia has already begun at Gold Coast University Hospital, which opened its doors to the trial in October 2025. The plan is to expand to Perth and Hobart, broadening the pool of participants and accelerating enrollment. Rohan Greenland, CEO of MS Australia, frames the expansion as both a scientific opportunity and a moral one. Progressive MS represents one of the largest unmet needs in neurology—there are few effective treatments, and the disease relentlessly worsens. By participating in PLATYPUS, Australians are contributing directly to a world-first research effort while also gaining access to a potential new therapy.
For Janine Watson, a Paralympian living with progressive MS and a member of MS Australia's Lived Experience Expert Panel, the speed matters profoundly. An effective treatment would restore something that progressive MS takes away: time. "It's about giving back time to people with progressive MS," she said, "and unfortunately with progressive MS, time is not our friend at all." That urgency—the sense that delay itself is a cost—runs through the entire rationale for the adaptive trial model. Melanie Kiely, CEO of MS Western Australia, which has funded PLATYPUS since its inception, echoes the point: the adaptive approach lets researchers move faster, deploy resources more efficiently, and focus on treatments with genuine potential. Over the next three years, as Stage 2 unfolds across Australian sites, the trial will test whether alpha lipoic acid can deliver on the promise that Stage 1 suggested.
Citations marquantes
The Octopus trial has shown that alpha lipoic acid was of benefit in Stage 1. While this is not proof that it works, it's a positive sign that it may be a benefit, which we're now going to test in Stage 2 over the next three years.— Professor Simon Broadley, Griffith University
It's about giving back time to people with progressive MS and unfortunately with progressive MS, time is not our friend at all.— Janine Watson, Paralympian and MS Australia Lived Experience Expert Panel member
Envie de l'histoire complète ?
Lire l'original sur Griffith University ↗
Business